Ítem
Solo Metadatos

Safety liver profile of teriflunomide versus interferon ? in multiple sclerosis: Systematic review and indirect comparison meta-analysis

Mostrar el registro sencillo de la publicación
dc.creatorSalas P.A.O.spa
dc.creatorParra C.O.spa
dc.creatorFlorez C.E.P.spa
dc.creatorGoez L.M.spa
dc.creatorVélez van Meerbeke, Alberto Franciscospa
dc.creatorRodriguez J.H.spa
dc.date.accessioned2020-05-25T23:57:13Z
dc.date.available2020-05-25T23:57:13Z
dc.date.created2018spa
dc.description.abstractObjectives: To compare the liver safety profile of interferon ? (IFN ?) and teriflunomide in patients with multiple sclerosis. Methods: A network meta-analysis was carried out following the Cochrane Collaboration methodology. All trials comparing all types of IFN ? with teriflunomide, or disease-modifying drugs, or placebo in RRMS were included. An indirect comparison network meta-analysis within a Bayesian framework with STATA (version 13.0) was done for this study. Results: The database searches yielded 284 titles, with 15 records as duplicates. One study was identified by manually searching. Thirteen articles were included in the systematic review. Twelve studies compared IFN ? (4203 patients) vs another DMT. Four studies evaluated the effectiveness and safety of teriflunomide (906 patients) vs another DMT. Six studies reported drug-induced liver injury as per the Hy's Law. However, only one study had a direct comparison and reported no cases of liver toxicity in either group, so it was not possible to estimate the OR. The indirect comparisons metanalysis shows that there was no statistically-significant difference between teriflunomide and IFN ? (OR 1.09, 95% CI 0.02–2.16). Conclusions: There were no significant difference when comparing IFN ? and teriflunomide in terms of liver failure or elevation of transaminases. © 2018eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1016/j.msard.2018.09.014
dc.identifier.issn22110348
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/22632
dc.language.isoengspa
dc.publisherElsevier B.V.spa
dc.relation.citationEndPage200
dc.relation.citationStartPage192
dc.relation.citationTitleMultiple Sclerosis and Related Disorders
dc.relation.citationVolumeVol. 26
dc.relation.ispartofMultiple Sclerosis and Related Disorders, ISSN:22110348, Vol.26,(2018); pp. 192-200spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85053856722&doi=10.1016%2fj.msard.2018.09.014&partnerID=40&md5=56fff51e5923b216bcbec854c32a836aspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordAlemtuzumabspa
dc.subject.keywordBeta interferonspa
dc.subject.keywordDaclizumabspa
dc.subject.keywordFingolimodspa
dc.subject.keywordGlatiramerspa
dc.subject.keywordPlacebospa
dc.subject.keywordTeriflunomidespa
dc.subject.keywordBeta interferonspa
dc.subject.keywordCrotonic acid derivativespa
dc.subject.keywordImmunologic factorspa
dc.subject.keywordTeriflunomidespa
dc.subject.keywordToluidine derivativespa
dc.subject.keywordArticlespa
dc.subject.keywordDrug efficacyspa
dc.subject.keywordDrug safetyspa
dc.subject.keywordHumanspa
dc.subject.keywordHypertransaminasemiaspa
dc.subject.keywordLiver functionspa
dc.subject.keywordLiver function testspa
dc.subject.keywordMeta analysisspa
dc.subject.keywordMultiple sclerosisspa
dc.subject.keywordSystematic reviewspa
dc.subject.keywordToxic hepatitisspa
dc.subject.keywordTreatment outcomespa
dc.subject.keywordComparative studyspa
dc.subject.keywordDrug effectspa
dc.subject.keywordLiverspa
dc.subject.keywordMultiple sclerosisspa
dc.subject.keywordToxic hepatitisspa
dc.subject.keywordChemical and drug induced liver injuryspa
dc.subject.keywordCrotonatesspa
dc.subject.keywordHumansspa
dc.subject.keywordImmunologic factorsspa
dc.subject.keywordInterferon-betaspa
dc.subject.keywordLiverspa
dc.subject.keywordMultiple sclerosisspa
dc.subject.keywordToluidinesspa
dc.subject.keywordInterferon ?spa
dc.subject.keywordLiver safety profilespa
dc.subject.keywordMultiple sclerosisspa
dc.subject.keywordTeriflunomidespa
dc.titleSafety liver profile of teriflunomide versus interferon ? in multiple sclerosis: Systematic review and indirect comparison meta-analysisspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Colecciones
Artículos